Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy. [PDF]
Jonasson E +8 more
europepmc +1 more source
Microalgae Hybrid Biosystem for Enhanced Oral Delivery of Rifaximin in Hepatic Encephalopathy Treatment. [PDF]
Wang K +8 more
europepmc +1 more source
Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomised Trial of Rifaximin for Covert Hepatic Encephalopathy. [PDF]
Saward G, Al-Ukaidey S.
europepmc +1 more source
A Novel Use of Tenapanor in Patients With Hepatic Encephalopathy: A Case Series. [PDF]
Yeo YH, Ayoub W, Rezaie A.
europepmc +1 more source
XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis. [PDF]
Lan Y, Zhao T, Xu Y, Ye H.
europepmc +1 more source
Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Narrative Review. [PDF]
Pyrsopoulos NT +3 more
europepmc +1 more source
Reversal of hepatic encephalopathy following a trans-scrotal approach to mesogonadal shunt embolization: a case report. [PDF]
Basha A, Emejulu I, Shah S.
europepmc +1 more source
Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomized Trial of Rifaximin for Covert Hepatic Encephalopathy. Authors' Reply. [PDF]
Inada H, Tanaka Y.
europepmc +1 more source
Use of Prucalopride in Severe Ileus in a Critically Ill Patient With Acute Alcoholic Hepatitis and Hepatic Encephalopathy. [PDF]
Swanson A, Schwarz JS, Bektas AN, Liu J.
europepmc +1 more source
Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study. [PDF]
Okajima H, Tagawa M, Fujisawa M, Ueda K.
europepmc +1 more source

